A Randomized, Double-Blind, Vehicle-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Topically Applied INM-755 Cream in Healthy Volunteers and to Study Suction Blisters as a Wound Healing Model.
Latest Information Update: 02 Jan 2025
At a glance
- Drugs Cannabinol (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions
- Acronyms CHDR1930; Study 101
- Sponsors InMed Pharmaceuticals
Most Recent Events
- 01 Jan 2025 Results (n=12) published in the European Journal of Pharmaceutical Sciences.
- 08 Sep 2022 According to an InMed Pharmaceuticals media release, enrollment is expected to complete by year end.
- 10 Nov 2021 Status changed from active, no longer recruiting to completed, according to an InMed Pharmaceuticals media release.